Recent Updates
Recently added Catalysts
ARWR Positive Sentiment

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

Tuesday, September 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Arrowhead Pharmaceuticals has announced a webinar scheduled for October 14, 2026, to discuss interim clinical data from its Phase 1/2a study of ARO-MAPT, aimed at treating Alzheimer's disease and other tauopathies. The event will feature Dr. Adam Boxer from UCSF, emphasizing the company's focus on its central nervous system pipeline.

Market Sentiment Analysis

POSITIVE FACTORS

  • Arrowhead Pharmaceuticals is advancing its investigational therapy ARO-MAPT.
  • The upcoming webinar will provide insights into the CNS pipeline.
  • Collaboration with UCSF highlights the credibility of the research.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+396%
120-day peak, hindsight
Typical move
2.4%
average across 5 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ARO-RAGE
Phase 2 · Asthma

Full Press Release Details

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will focus on investigational therapy ARO-MAPT and Arrowhead’s central nervous system (CNS) pipeline. The webinar will feature a presentation from Adam Boxer, M.D., Ph.D., Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF), where he directs

Frequently Asked Questions

What is the focus of the upcoming Arrowhead webinar?

The webinar will focus on the investigational therapy ARO-MAPT and Arrowhead's CNS pipeline.

Who will present at the Arrowhead webinar?

Dr. Adam Boxer from UCSF will present at the webinar.

When is the Arrowhead webinar scheduled?

The webinar is scheduled for October 14, 2026, at 11:30 AM PDT.

What is ARO-MAPT used for?

ARO-MAPT is being investigated for the treatment of Alzheimer's disease and other tauopathies.

ShareAdd on Google
Tags: ARWR Arrowhead Pharmaceuticals ARO-MAPT Alzheimer's disease tauopathies CNS pipeline
Last updated: Sep 29, 2026

Biotech snapshot

Cash runway
$1602M liquidity · $59M/mo burn
~25 mo
Minimal dilution risk
Lead asset
ARO-RAGEPhase 2
Asthma →

Catalyst track record

+396%
best trade around ARWR's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ARWR.

See every catalyst's timing & PoA →